Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$139.68 USD

139.68
634,142

+1.96 (1.42%)

Updated Jul 17, 2024 04:00 PM ET

After-Market: $139.70 +0.02 (0.01%) 4:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (67 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

Medtronic's (MDT) Newest Evolut TAVR System Gets FDA Approval

by Zacks Equity Research

Medtronic (MDT) announces the FDA approval of the newest-generation Evolut TAVR system for the treatment of symptomatic severe aortic stenosis.

McKesson (MCK) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about McKesson's (MCK) strength in its Biologics business.

Chemed (CHE) Up 2.5% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

GE HealthCare's (GEHC) PVA to Aid in Capturing Prostate Volume

by Zacks Equity Research

GE HealthCare (GEHC) announces the launch of Prostate Volume Assist AI-enabled urology software feature, which is likely to boost prostate imaging, capture prostate volume and increase workflow.

3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio

by Zacks Equity Research

Expanding product portfolio and high prospects for POC raise optimism for Inogen (INGN) stock.

Here's Why You Should Add Lantheus (LNTH) to Your Portfolio

by Zacks Equity Research

Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.

Boston Scientific (BSX) and Scivita Medical Expand Partnership

by Zacks Equity Research

Boston Scientific (BSX) and Scivita Medical announce an expanded strategic cooperation arrangement.

Here's Why Investors Should Retain Thermo Fisher (TMO) Stock

by Zacks Equity Research

Strength in end markets and strategic collaborations bode well for Thermo Fisher (TMO).

Accuray's (ARAY) CyberKnife Improves Prostate Cancer Treatment

by Zacks Equity Research

Accuray (ARAY) announces the latest data that supports the use of its CyberKnife System in the treatment of recurrent prostate cancer with stereotactic body radiation therapy.

DexCom (DXCM) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about DexCom's (DXCM) strong product portfolio.

Stryker's (SYK) Latest Launch to Streamline Procedural Workflows

by Zacks Equity Research

Stryker's (SYK) latest addition to its Gamma legacy is expected to streamline workflows and enhance usability.

Myriad Genetics (MYGN) Wins Foundational Patent for MRD Assay

by Zacks Equity Research

Myriad Genetics' (MYGN) new patent grant is likely to bolster the ability to deliver a tumor-informed, high-definition MRD assay to the market.

Reasons to Add Cencora (COR) Stock in Your Portfolio Now

by Zacks Equity Research

Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Masimo (MASI) Plans Consumer Business Spin-Off to Drive Growth

by Zacks Equity Research

Masimo (MASI) is evaluating a proposed separation of its consumer audio and consumer health product business in a bid to improve the profitability of the healthcare business.

Three Reasons to Retain Avantor (AVTR) Stock in Your Portfolio

by Zacks Equity Research

Avantor's (AVTR) strong product portfolio raises optimism about the stock.

Veeva Systems' (VEEV) Vault EDC Witnesses Increasing Adoption

by Zacks Equity Research

Veeva Systems' (VEEV) Vault EDC is likely to enable companies to build a modern clinical data foundation.

Reasons to Add Veeva Systems (VEEV) to Your Portfolio Now

by Zacks Equity Research

Veeva's strong product demand and strategic deals raise optimism about the stock.

GE HealthCare (GEHC) to Sell IONIC's FDA-Cleared nCommand Lite

by Zacks Equity Research

GE HealthCare (GEHC) announces the FDA approval of IONIC Health's nCommand Lite technology, which it will distribute for multi-vendor, multi-modality remote operations purposes exclusively.

Reasons to Retain Intuitive Surgical (ISRG) in Your Portfolio

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.

Charles River (CRL) Extends Gene Therapy Deal With NUS Medicine

by Zacks Equity Research

Charles River (CRL) announces the extension of the gene therapy manufacturing alliance with NUS Medicine.

Here's Why You Should Buy Align Technology (ALGN) Stock Now

by Zacks Equity Research

Investors remain optimistic about Align Technology (ALGN), backed by Invisalign's strong potential and impressive collaborations.

Are Investors Undervaluing DaVita (DVA) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Tandem Diabetes (TNDM) Gains From Innovation Amid Competition

by Zacks Equity Research

Tandem Diabetes (TNDM), in 2024, intends to advance its AID algorithm and expand its indications to include people living with Type 2 diabetes.

Stryker (SYK) Acquires SERF SAS to Aid Its Orthopedic Segment

by Zacks Equity Research

Stryker (SYK) completes its acquisition of SERF SAS, a France-based joint replacement company. With this acquisition, Stryker aims to boost its orthopedic division in the European region.

Bruker Corporation (BRKR) Hits 52-Week High: What's Driving It?

by Zacks Equity Research

Bruker Corporation (BRKR) outperforms the industry due to its strengthening portfolio and robust quarterly results.